SMMT Stock Price | Summit Therapeutics PLC P/E, Revenue, EPS, & Forecasts

Summit Therapeutics PLC • SMMT

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Summit Therapeutics PLC

Ticker

SMMT

Trading on

NASDAQ

ISIN

US86627T1088

Industry

Biotechnology

Sector

Healthcare

CEO

Robert W. Duggan

Headquarters

601 Brickell Key Drive, Miami, FL, United States, 33131

Employees

159

Website

smmttx.com

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Metrics

BasicAdvanced

Market cap

$14B

P/E ratio

EPS

-$1.25

Dividend Yield

0.00%

Beta

-1.53

Forward P/E ratio

EBIDTA

$-935M

Ex dividend date

Price & volume

Market cap

$14B

Average daily volume

2.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

753.9

Price to book

71.13

Earnings

EPS

-$1.25

EPS estimate (current quarter)

-$0.04

EPS estimate (next quarter)

-$0.14

EBITDA

$-935M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

-1.53

52-week High

$36.91

52-week Low

$15.55

50-day moving average

$19.39

200-day moving average

$22.02

Short ratio

9.18

Short %

26.38%

Management effectiveness

ROE (TTM)

-292.49%

ROA (TTM)

-152.88%

Profit margin

0.00%

Gross profit margin

$0.7M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-100.00%

Share stats

Outstanding Shares

744M

Float

125M

Insiders %

86.05%

Institutions %

14.41%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 10 analysts.

Average price target

$32.39

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.07

-$0.08

12.50%

Q4 • 24Beat

-$0.07

0.73%

Q1 • 25Beat

-$0.12

-$0.09

-33.33%

Q2 • 25Missed

-$0.23

-$0.10

-124.32%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-232M

-∞%

Q2 • 25

$0M

$-232M

-∞%

Q3 • 25

NaN%

-0.00%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$262M

$69.5M

26.54%

Q2 • 25

$262M

$69.5M

26.54%

Q3 • 25

0.00%

-0.00%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-95M

$151M

$34.7M

$-95.1M

Q2 • 25

$-93.1M

$0M

$33.8M

$-93.2M

Q3 • 25

-2.04%

-100.00%

-2.44%

-2.04%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Summit Therapeutics PLC share?

Summit Therapeutics PLC shares are currently traded for undefined per share.

How many shares does Summit Therapeutics PLC have?

Summit Therapeutics PLC currently has 744M shares.

Does Summit Therapeutics PLC pay dividends?

No, Summit Therapeutics PLC doesn't pay dividends.

What is Summit Therapeutics PLC 52 week high?

Summit Therapeutics PLC 52 week high is $36.91.

What is Summit Therapeutics PLC 52 week low?

Summit Therapeutics PLC 52 week low is $15.55.

What is the 200-day moving average of Summit Therapeutics PLC?

Summit Therapeutics PLC 200-day moving average is $22.02.

Who is Summit Therapeutics PLC CEO?

The CEO of Summit Therapeutics PLC is Robert W. Duggan.

How many employees Summit Therapeutics PLC has?

Summit Therapeutics PLC has 159 employees.

What is the market cap of Summit Therapeutics PLC?

The market cap of Summit Therapeutics PLC is $14B.

What is the P/E of Summit Therapeutics PLC?

The current P/E of Summit Therapeutics PLC is null.

What is the EPS of Summit Therapeutics PLC?

The EPS of Summit Therapeutics PLC is -$1.25.

What is the PEG Ratio of Summit Therapeutics PLC?

The PEG Ratio of Summit Therapeutics PLC is 0.

What do analysts say about Summit Therapeutics PLC?

According to the analysts Summit Therapeutics PLC is considered a buy.